Answer a few questions using Lilly Trial Match to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Match to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

5  Enrolling
9  Total Trials
Pinned
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Enrolling
Conditions: Alzheimer's Disease
Trial Name
TRAILRUNNER-ALZ 1
Drugs: Remternetug (LY3372993)
Age
60-85
Phase
III
Pinned
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Enrolling
Conditions: Alzheimer's Disease
Drugs: donanemab
Age
60-85
Phase
III
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
Enrolling
Conditions: Gaucher Disease, Type 1
Trial Name
PROCEED
Drugs: LY3884961, an investigational gene therapy
Age
18-65
Phase
II
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Enrolling
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 3
Drugs: Donanemab, LY3002813
Age
65-80
Phase
III
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Enrolling
Conditions: Alzheimer's Disease
Drugs: Donanemab
Age
60-85
Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
Not the right fit? Sign up to receive Lilly Trial Alerts to find out about new trials.
4 
Completed Enrollment
9  Total Trials
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
PROSPECT-ALZ
Drugs: LY3372689
Age
60-85
Phase
II
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-EXT
Drugs: Donanemab
Age
≥60
Phase
II
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
Completed Enrollment
Conditions: Alzheimer's Disease
Drugs: LY3372993
Age
18-85
Phase
I
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 2
Drugs: Donanemab
Age
60-85
Phase
III